HIMS
NYSEHims & Hers Health, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 48 recent filings. 41 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Okupe Oluyemi Chief Financial Officer | Option exercise | 7.16K | $5.01 | $35,886.63 | 2026-07-17 |
Okupe Oluyemi Chief Financial Officer | Sell (open market) | 7.16K | $31.99 | $229,168.01 | 2026-07-17 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 7.16K | $0.00 | — | 2026-07-17 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 7.16K | $5.01 | $35,886.63 | 2026-07-06 |
Okupe Oluyemi Chief Financial Officer | Sell (open market) | 7.16K | $36.49 | $261,351.37 | 2026-07-06 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 7.16K | $0.00 | — | 2026-07-06 |
Carroll Patrick Harrison Chief Medical Officer | Sell (open market) | 23.73K | $35.00 | $830,410.00 | 2026-06-18 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 6.38K | $5.01 | $31,943.76 | 2026-06-22 |
Okupe Oluyemi Chief Financial Officer | Sell (open market) | 18.2K | $34.03 | $619,216.61 | 2026-06-22 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 6.38K | $0.00 | — | 2026-06-22 |
Carroll Patrick Harrison Chief Medical Officer | Option exercise | 25.93K | — | — | 2026-06-15 |
Carroll Patrick Harrison Chief Medical Officer | Tax withholding | 8.31K | $30.17 | $250,712.70 | 2026-06-15 |
Carroll Patrick Harrison Chief Medical Officer | Option exercise | 8.15K | $0.00 | — | 2026-06-15 |
Carroll Patrick Harrison Chief Medical Officer | Option exercise | 4.84K | $0.00 | — | 2026-06-15 |
Carroll Patrick Harrison Chief Medical Officer | Option exercise | 3.53K | $0.00 | — | 2026-06-15 |
Carroll Patrick Harrison Chief Medical Officer | Option exercise | 9.41K | $0.00 | — | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 71.62K | — | — | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Tax withholding | 39.54K | $30.17 | $1,192,951.97 | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 18.33K | $0.00 | — | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 22.99K | $0.00 | — | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 11.48K | $0.00 | — | 2026-06-15 |
Okupe Oluyemi Chief Financial Officer | Option exercise | 18.81K | $0.00 | — | 2026-06-15 |
Autor Deborah M. Director, Chief Policy Officer | Option exercise | 32.92K | — | — | 2026-06-15 |
Autor Deborah M. Director, Chief Policy Officer | Tax withholding | 15.4K | $30.17 | $464,497.32 | 2026-06-15 |
Autor Deborah M. Director, Chief Policy Officer | Option exercise | 32.92K | $0.00 | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Option exercise | 86.26K | — | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Tax withholding | 47.7K | $30.17 | $1,439,078.83 | 2026-06-15 |
Chi Michael Chief Operating Officer | Sell (open market) | 14.03K | $31.50 | $441,850.50 | 2026-06-17 |
Chi Michael Chief Operating Officer | Option exercise | 16.5K | $0.00 | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Option exercise | 16.3K | $0.00 | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Option exercise | 19.36K | $0.00 | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Option exercise | 10.6K | $0.00 | — | 2026-06-15 |
Chi Michael Chief Operating Officer | Option exercise | 23.51K | $0.00 | — | 2026-06-15 |
Becklund Irene PAO | Option exercise | 15.97K | — | — | 2026-06-15 |
Becklund Irene PAO | Tax withholding | 5.87K | $30.17 | $177,097.90 | 2026-06-15 |
Becklund Irene PAO | Sell (open market) | 7.57K | $30.25 | $229,083.25 | 2026-06-16 |
Becklund Irene PAO | Sell (open market) | 4.49K | $31.50 | $141,435.00 | 2026-06-17 |
Becklund Irene PAO | Option exercise | 2.29K | $0.00 | — | 2026-06-15 |
Becklund Irene PAO | Option exercise | 4.07K | $0.00 | — | 2026-06-15 |
Becklund Irene PAO | Option exercise | 4.34K | $0.00 | — | 2026-06-15 |
Becklund Irene PAO | Option exercise | 1.39K | $0.00 | — | 2026-06-15 |
Becklund Irene PAO | Option exercise | 3.88K | $0.00 | — | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Option exercise | 42.26K | — | — | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Tax withholding | 23.32K | $30.17 | $703,413.55 | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Option exercise | 12.22K | $0.00 | — | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Option exercise | 12.1K | $0.00 | — | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Option exercise | 6.18K | $0.00 | — | 2026-06-15 |
Boughton Soleil Chief Legal Officer | Option exercise | 11.76K | $0.00 | — | 2026-06-15 |
Source: SEC EDGAR Forms 4/4A (CIK 1773751). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$ASTS $HIMS $ONDS
Mission: $500K Portfolio by 2030 Current Portfolio: $205K My 5-year price targets: $HIMS $27 → $120 $ASTS $59 → $446 $ONDS $8 → $30 $PNG.V $6 → $26 This portfolio is built around long-term themes: • AI infrastructure • Cloud & compute • Fintech • Digital health • Space communications Will every target be reached? Probably not. But if even a few of these companies execute as expected over the next five years, the upside could be meaningful. The goal isn't to predict every move. It's to own high-quality growth businesses and give them time to compound. Mission: $500K by 2030. Do you think it's achievable?
$HIMS why are like the last 5 posts all AI bots saying “be careful”?
$HOOD WE ABOUT TO PUMP SO HARD TONIGHT AND THIS WEEK $HIMZ $HOOW $HIMS
$HIMS is one I’m watching carefully because the chart is starting to show some warning signs. The recent channel retest doesn’t look as strong as bulls would want. Price is showing signs of rejection, and the key level for me is the 200-week moving average. If that support fails, the downside risk increases and the stock could be forced into a deeper reset. I know it’s never popular to be bearish on a name people love, but the market doesn’t care about opinions — it follows price. Last time I pointed out weakness around the $37 area, many disagreed, and the stock eventually pulled back toward $15. Now I’m watching whether $HIMS can prove the bears wrong or if more downside is ahead. Nice to see you after the bell. What's your focus for tomorrow? Enjoy the evening.
Fair warning on $HIMS: this is NOT bullish! Shares coiling intraday through the $26.86-$28.94 demand zone to settle at $27.77. Price is showing clear rejection on the channel retest. Lose the 200WMA and we drop straight to $10. Got hate calling $37 down to $15 history is repeating. Smart money is watching closely! Market opportunities don't send invitations. Stay connected as the next important move begins to develop. Sharing my daily market observations and ideas.
$HIMS One week to the next major event. The market will be watching growth, margins, and any updates on the business direction. Volatility usually picks up around these moments, so I’m watching how price reacts rather than guessing the outcome.
$HIMS Historic earnings ahead and you want to be cautious
$HIMS
$HIMS I’m staying cautious here. The recent move is showing some weakness, and the key question is whether buyers can defend the major support area. If that level fails, the stock could face more downside pressure.
$HIMS The stock bounced right where buyers needed to show up, holding the trendline and the $25 support zone. A reclaim of $28 would put $30 and $35 back in play. The bigger thing I’m watching is the privacy risk around healthcare data. The chart can look good, but sentiment can change quickly if that issue gets worse.
Some of the biggest stocktwits favorites are trading well below their 52-week highs. $OKLO $38.83 (-80%) $SOUN $6.13 (-72%) $TE $4.17 (-67%) $AAOI $94.32 (-60%) $HIMS $27.77 (-58%) A big drawdown doesn't automatically make a stock a bargain. The best opportunities are where fundamentals remain intact while sentiment has collapsed. My focus would be on businesses with durable growth, improving cash flow, and long-term AI or infrastructure tailwinds—not simply the biggest declines. Which names are you buying here?
Latest news
2 Growth Stocks with Explosive Upside and 1 That Underwhelm
Here Comes the Next Wave of GLP-1s. They’ll Treat a Lot More Than Obesity.
HIMS Stock Eyes 4-Week Losing Streak: Legal Woes Fuel ‘Very High’ Uncertainty As Analyst Sticks To ‘No Moat’ Call
Is The Sharp Drop In Hims & Hers Health Stock A Reason To Buy?
2 Unprofitable Stocks for Long-Term Investors and 1 We Ignore
HIMS Stock in Focus as FTC Lawsuit Takes Aim at Hims & Hers Business Practices
Hims & Hers Health (HIMS) Faces FTC Lawsuit Over Health Data And Billing
FTC sues Hims & Hers, alleging it shared health data with Meta, Snap
Sector Update: Healthcare Stocks Softer Late Afternoon
Hims & Hers Stock Plunges After FTC Sues Over Alleged Privacy Violations
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.